Please login to the form below

Not currently logged in
Email:
Password:

Addyi

This page shows the latest Addyi news and features for those working in and with pharma, biotech and healthcare.

Rare disease therapies head the ‘class of 2015’

Rare disease therapies head the ‘class of 2015’

for 'female Viagra' after the FDA backed Addyi (flibanserin) for hypoactive sexual desire disorder in women. ... South Korea. evolocumab. Repatha. hypercholesterolaemia. PCSK9 inhibitor. Amgen. EU. flibanserin. Addyi.

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    This month the deal was the purchase of Sprout Pharmaceuticals for $1bn cash in two instalments of $500m bringing the recently approved product Addyi (flibanserin) which is used for hypoactive sexual

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics